Urinary EpCAM in urothelial bladder cancer patients: Characterisation and evaluation of biomarker potential

British Journal of Cancer

Volumn 110, Issue 3, 2014, Pages 679-685

  Bryan, R T ^a   Shimwell, N J ^a   Wei, W ^a   Devall, A J ^a   Pirrie, S J ^a   James, N D ^a   Zeegers, M P ^a,b   Cheng, K K ^a   Martin, A ^a   Ward, D G ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

biomarker; bladder cancer; EpCAM; prognosis; urine

Indexed keywords

CREATININE; EPITHELIAL CELL ADHESION MOLECULE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEGLYCOSYLATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN URINE LEVEL; RECEIVER OPERATING CHARACTERISTIC; UROTHELIAL BLADDER CANCER; VERY ELDERLY; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84893757621     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.744     Document Type: Article

References (29)

1. Abe H, Kuroki M, Imakiire T, Yamauchi Y, Yamada H, Arakawa F, Kuroki M (2002) Preparation of recombinant MK-1/Ep-CAM and establishment of an ELISA system for determining soluble MK-1/Ep-CAM levels in sera of cancer patients. J Immunol Methods 270: 227-233.
2. Allory Y, Beukers W, Sagrera A, Flández M, Marqués M, Márquez M, van der Keur K, Dyrskjot L, Lurkin I, Vermeij M, Carrato A, Lloreta J, Lorente J, Carrillo-de Santa Pau E, Masius R, Kogevinas M, Steyerberg E, van Tilborg A, Abas C, Orntoft T, Zuiverloon T, Malats N, Zwarthoff E, Real F (2013) Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 65(2): 360-366.
3. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, Rouprêt M. European Association of Urology (2011) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59: 997-1008.
4. Brunner A, Prelog M, Verdorfer I, Tzankov A, Mikuz G, Ensinger C (2008) EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder. J Clin Pathol 61: 307-310.
5. Burger M, Catto J, Dalbagni G, Grossman H, Herr H, Karakiewicz P, KassoufW, Kiemeney L, La Vecchia C, Shariat S, Lotan Y (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63: 234-241.
6. Chaves-Pérez A, Mack B, Maetzel D, Kremling H, Eggert C, Harréus U, Gires O (2013) EpCAM regulates cell cycle progression via control of cyclin D1 expression. Oncogene 32: 641-650.
7. Chong J, Speicher D (2001) Determination of disulfide bond assignments and N-glycosylation sites of the human gastrointestinal carcinoma antigen GA733-2 (CO17-1A, EGP, KS1-4, KSA, and Ep-CAM). J Biol Chem 276: 5804-5813.
8. Coglievina M, Guarnaccia C, Zlatev V, Pongor S, Pintar A (2013) Jagged-1 juxtamembrane region: biochemical characterization and cleavage by ADAM17 (TACE) catalytic domain. Biochem Biophys Res Commun 432: 666-671.
9. Hennenlotter J, Huber S, Todenhöfer T, Kuehs U, Schilling D, Aufderklamm S, Gakis G, Schwentner C, Stenzl A (2011) Point-of-care tests for bladder cancer: the influencing role of hematuria. Adv Urol 2011: doi:10.1155/2011/937561.
10. James N, Hussain S, Hall E, Jenkins P, Tremlett J, Rawlings C, Crundwell M, Sizer B, Sreenivasan T, Hendron C, Lewis R, Waters R, Huddart R. Investigators B (2012) Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 366: 1477-1488.
11. Kimura H, Kato H, Faried A, Sohda M, Nakajima M, Fukai Y, Miyazaki T, Masuda N, Fukuchi M, Kuwano H (2007) Prognostic significance of EpCAM expression in human esophageal cancer. Int J Oncol 30: 171-179.
12. Kowalski M, Entwistle J, Cizeau J, Niforos D, Loewen S, Chapman W, MacDonald G (2010) A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of non muscle-invasive bladder cancer in BCG refractory and BCG-intolerant patients. Drug Des Devel Ther 15: 313-320.
13. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, Kieu C, Papior P, Baeuerle P, Munz M, Gires O (2009) Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 11: 162-171.
14. Miah S, Dudziec E, Drayton R, Zlotta A, Morgan S, Rosario D, Hamdy F, Catto J (2012) An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer. Br J Cancer 107: 123-128.
15. Miyake M, Goodison S, Giacoia E, Rizwani W, Ross S, Rosser C (2012a) Influencing factors on the NMP-22 urine assay: an experimental model. BMC Urol 12: doi:10.1186/1471-2490-12-23.
16. Miyake M, Goodison S, Rizwani W, Ross S, Grossman H, Rosser C (2012b) Urinary BTA: indicator of bladder cancer or of hematuria. World J Urol 30: 869-873.
17. Mowatt G, Zhu S, Kilonzo M, Boachie C, Fraser C, Griffiths T, N'Dow J, Nabi G, Cook J, Vale L (2010) Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess 14: 1-331.
18. Okegawa T, Hayashi K, Hara H, Nutahara K, Higashihara E (2010) Immunomagnetic quantification of circulating tumor cells in patients with urothelial cancer. Int J Urol 17: 254-258.
19. Patriarca C, Colombo P, Pio Taronna A, Wesseling J, Franchi G, Guddo F, Naspro R, Macchi R, Giunta P, Di Pasquale M, Parente M, Arizzi C, Roncalli M, Campo B (2009) Cell discohesion and multifocality of carcinoma in situ of the bladder: new insight from the adhesion molecule profile (e-cadherin, Ep-CAM, and MUC1). Int J Surg Pathol 17: 99-106.
20. Petsch S, Gires O, Rüttinger D, Denzel S, Lippold S, Baeuerle P, Wolf A (2011) Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110. MAbs 3: 31-37.
21. Ploeg M, Aben K, Kiemeney L (2009) The present and future burden of urinary bladder cancer in the world. World J Urol 27: 289-293.
22. Ralhan R, He H, So A, Tripathi S, Kumar M, Hasan M, Kaur J, Kashat L, MacMillan C, Chauhan S, Freeman J, Walfish P (2010) Nuclear and cytoplasmic accumulation of Ep-ICD is frequently detected in human epithelial cancers. PLoS One 5: e14130.
23. Reinert T, Modin C, Castano F, Lamy P, Wojdacz T, Hansen L, Wiuf C, Borre M, Dyrskjøt L, Orntoft T (2011) Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin Cancer Res 17: 5582-5592.
24. Shimwell N, Bryan R, Wei W, James N, Cheng K, Zeegers M, Johnson P, Martin A, Ward D (2013) Combined proteome and transcriptome analyses for the discovery of urinary biomarkers for urothelial carcinoma. Br J Cancer 108: 1854-1861.
25. Stenzl A, Cowan N, De Santis M, Kuczyk M, Merseburger A, Ribal M, Sherif A, Witjes J (2011) Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 59: 1009-1018.
26. Szala S, Froehlich M, Scollon M, Kasai Y, Steplewski Z, Koprowski H, Linnenbach A (1990) Molecular cloning of cDNA for the carcinomaassociated antigen GA733-2. Proc Natl Acad Sci USA 87: 3542-3546.
27. Tilki D, Burger M, Dalbagni G, Grossman H, Hakenberg O, Palou J, Reich O, Rouprêt M, Shariat S, Zlotta A (2011) Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol 60: 484-492.
28. Zeegers M, Bryan R, Langford C, Billingham L, Murray P, Deshmukh N, Hussain S, James N, Wallace D, Cheng K (2010) The West Midlands Bladder Cancer Prognosis Programme: rationale and design. BJU Int 105: 784-788.
29. Zuiverloon T, Beukers W, van der Keur K, Nieuweboer A, Reinert T, Dyrskjot L, Orntoft T, Zwarthoff E (2013) Combinations of urinary biomarkers for surveillance of patients with incident nonmuscle invasive bladder cancer: the European FP7 UROMOL project. J Urol 189: 1945-1951.